[ Price : $8.95]
FDA issues Alar Pharmaceuticals an untitled letter over promotional materials for its investigational ketamine drug, ALA-3000, bec...[ Price : $8.95]
FDAs approval of new drugs is increasingly being supported by fewer clinical studies.[ Price : $8.95]
The agency approves Priovant Therapeutics Lisraya (brepocitinib) tablets for treating dermatomyositis in adults.[ Price : $8.95]
Akin Gump attorneys highlight major issues in the PDUFA 8 commitment letter that is now open for public comment.[ Price : $8.95]
MasterControl issues its 2026 life sciences regulatory readiness playbook demonstrating the significant ways in which the FDA Qual...[ Price : $8.95]
The U.S. Court of Appeals for the Fifth Circuit upholds FDAs decision to remove tirzepatide from the agencys drug shortage list, a...[ Price : $8.95]
Reed Smith attorney James Beck says courts so far have rejected all arguments citing the Supreme Courts Loper Bright decision as a...[ Price : $8.95]
Attorneys from Arnall Golden Gregory examine and offer advice on FDAs intensified scrutiny of drug advertising, advising companies...